Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force. Cohn SL, et al. Among authors: garaventa a. J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047291 Free PMC article.
Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for Neuroblastoma.
De Bernardi B, Carli M, Casale F, Corciulo P, Cordero di Montezemolo L, De Laurentis C, Bagnulo S, Brisigotti M, Marchese N, Garaventa A, et al. De Bernardi B, et al. Among authors: garaventa a. J Clin Oncol. 1992 Dec;10(12):1870-8. doi: 10.1200/JCO.1992.10.12.1870. J Clin Oncol. 1992. PMID: 1453202
Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma.
Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, Cordero di Montezemolo L, Di Tullio MT, Bagnulo S, Mancini A, Carli M, Pession A, Arrighini A, Di Cataldo A, Tamaro P, Iasonni V, Taccone A, Rogers D, Boni L; Italian Cooperative Group dor Neuroblastoma. Garaventa A, et al. J Clin Oncol. 1993 Sep;11(9):1770-9. doi: 10.1200/JCO.1993.11.9.1770. J Clin Oncol. 1993. PMID: 8355044
Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D, Gadner H, Chauvin F. Ladenstein R, et al. Among authors: garaventa a. J Clin Oncol. 1998 Mar;16(3):953-65. doi: 10.1200/JCO.1998.16.3.953. J Clin Oncol. 1998. PMID: 9508178
Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry.
Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, Luksch R, Di Cataldo A, Favre C, D'Angelo P, Zanazzo GA, Arcamone G, Izzi GC, Gigliotti AR, Pastore G, De Bernardi B. Haupt R, et al. Among authors: garaventa a. J Clin Oncol. 2010 May 10;28(14):2331-8. doi: 10.1200/JCO.2009.24.8351. Epub 2010 Mar 29. J Clin Oncol. 2010. PMID: 20351331
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J. Rubie H, et al. Among authors: garaventa a. J Clin Oncol. 2011 Feb 1;29(4):449-55. doi: 10.1200/JCO.2010.29.5196. Epub 2010 Dec 20. J Clin Oncol. 2011. PMID: 21172879 Clinical Trial.
Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
Di Cataldo A, Agodi A, Balaguer J, Garaventa A, Barchitta M, Segura V, Bianchi M, Castel V, Castellano A, Cesaro S, Couselo JM, Cruz O, D'Angelo P, De Bernardi B, Donat J, de Andoin NG, Hernandez MI, La Spina M, Lillo M, Lopez-Almaraz R, Luksch R, Mastrangelo S, Mateos E, Molina J, Moscheo C, Mura R, Porta F, Russo G, Tondo A, Torrent M, Vetrella S, Villegas JA, Viscardi E, Zanazzo GA, Cañete A. Di Cataldo A, et al. Among authors: garaventa a. Clin Transl Oncol. 2017 Jan;19(1):76-83. doi: 10.1007/s12094-016-1505-1. Epub 2016 Apr 4. Clin Transl Oncol. 2017. PMID: 27041689
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN). Ladenstein R, et al. Among authors: garaventa a. Lancet Oncol. 2017 Apr;18(4):500-514. doi: 10.1016/S1470-2045(17)30070-0. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28259608 Clinical Trial.
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study.
Amoroso L, Erminio G, Makin G, Pearson ADJ, Brock P, Valteau-Couanet D, Castel V, Pasquet M, Laureys G, Thomas C, Luksch R, Ladenstein R, Haupt R, Garaventa A; SIOPEN Group. Amoroso L, et al. Among authors: garaventa a. Cancer Res Treat. 2018 Jan;50(1):148-155. doi: 10.4143/crt.2016.511. Epub 2017 Mar 21. Cancer Res Treat. 2018. PMID: 28324923 Free PMC article. Clinical Trial.
302 results